Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
We are thrilled to highlight a recent interview in OnDrug Delivery (Issue 171) featuring our CEO, Dr. Patrick Anquetil. Titled "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors," the article tackles the significant environmental challenges and extensive waste generated by single-use autoinjectors in the self-injection market. Dr. Anquetil presents a compelling case for pivoting towards reusable electromechanical autoinjectors as a more sustainable and potentially cost-effective path forward. The discussion showcases Portal Instruments' solution, PRIME Nexus – a flexible, needle-based reusable platform – and explores broader insights into reducing waste, the benefits of connected reusable devices, and why sustainable innovation should ultimately lead to lower healthcare costs. The full article can be read in OnDrug Delivery.
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Today Portal Instruments announced the signing of a multi-million-dollar development agreement with a leading biotech company to advance its large-volume, reusable autoinjector, PRIME NEXUS™, toward clinical readiness in Q1 2027.
Please fill out the details below and we will get back to you shortly.